SNDX
Syndax Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.77B
P/E Ratio
—
EPS
$-2.79
Beta
0.41
52W High
$25.59
52W Low
$8.59
50-Day MA
$22.44
200-Day MA
$19.18
Dividend Yield
—
Profit Margin
-112.00%
Forward P/E
—
PEG Ratio
0.00
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company is headquartered in Waltham, Massachusetts.
Fundamentals
| Revenue (TTM) | $217.17M |
| Gross Profit (TTM) | $-50.33M |
| EBITDA | $-223.77M |
| Operating Margin | -52.70% |
| Return on Equity | -189.50% |
| Return on Assets | -25.10% |
| Revenue/Share (TTM) | $2.49 |
| Book Value | $0.74 |
| Price-to-Book | 42.43 |
| Price-to-Sales (TTM) | 8.14 |
| EV/Revenue | 8.06 |
| EV/EBITDA | -105.26 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 223.60% |
| Shares Outstanding | $88.61M |
| Float | $79.03M |
| % Insiders | 1.72% |
| % Institutions | 115.94% |
Historical Volatility
HV 10-Day
42.06%
HV 20-Day
59.67%
HV 30-Day
53.73%
HV 60-Day
50.05%
HV Rank
50.8%
Volatility is currently contracting
Analyst Ratings
Consensus ($39.25 target)
2
Strong Buy11
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026